Clinical trials: Malignant Ascites
Malignant Ascites
Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites
This projectis aim to evaluate the efficacy of immune checkpoint inhibitor (pembrolizumab or nivolumab) on the malignant ascites of patients with advanced gastric, pancreatic and biliary tract cancers.
- Trial name
- NCT05745233
- Testing
- Nivolumab, Pembrolizumab
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- China Medical University Hospital
Cancer
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005860
- Testing
- floxuridine, leucovorin calcium, oxaliplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Refractory Malignant Ascites
Analysis of Patients Treated With Bevacizumab Intraperitoneal for the Treatment of Refractory Malignant Ascites
The refractory malignant ascites is a complication of advanced stages of many cancer types. It is characterized clinically by abdominal pressure sensation, shortness of breath and pelvic pain.
- Trial name
- BEVASCITE (NCT02891369)
- Testing
- No intervention. Descriptive study
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Digestive System Neoplasms
IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx
This study is a prospective, non-randomized, dual-cohort Phase II clinical trial designed to explore the efficacy and safety of radiotherapy combined with intraperitoneal injection of Recombinant Mutant Human Tumor Necrosis…
- Trial name
- NCT07196540
- Testing
- Radiotherapy for large-volume abdominal lesions + whole peritoneal cavity low-dose radiotherapy + rmhTNF-NC + tislelizumab
- Volunteers
- 78 people
- Sponsor
- Sun Yat-sen University
Malignant Ascites Due to Epithelial Carcinoma
Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites
This phase II single arm, open-label study investigate the safety of a second cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after treatment in the CASIMAS…
- Trial name
- SECIMAS (NCT01065246)
- Testing
- catumaxomab
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Neovii Biotech
STOMACH NEOPLASM, Gastric Cancer
Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites
To investigate efficacy and safety of lenvatinib in combination with nivolumab plus chemotherapy in gastric cancer patients with peritoneal metastasis and grade ≥ 2 ascites.
- Conditions
- STOMACH NEOPLASM, Gastric Cancer, Gastric Cancer Adenocarcinoma Metastatic
- Trial name
- NCT07149090
- Testing
- Lenvatinib
- Where
- South Korea
- Volunteers
- 61 people
- Sponsor
- Asan Medical Center
Ascites, Malignant
Quality of Life of Patients Who Have Rocket Indwelling Pleural Catheter Drainage or Repeated Large Volume Paracentesis
Ascites (accumulation of fluid in the abdominal cavity) is a common problem which can lead to distressing symptoms. When caused by cancer, management options are chemotherapy, diuretics and ascitic drainage.
- Trial name
- NCT03550690
- Testing
- Large Volume Paracentesis, Rocket Indwelling Pleural Catheter
- Volunteers
- 20 people
- Sponsor
- Gloucestershire Hospitals NHS Foundation Trust
Malignant Ascites
Retrospective Study in the Use of the Alfapump and the Treatment of Malignant Ascites
Treatment of malignant ascites with the alfapump offers a new treatment option for this patient group. So far, there is no systematic analysis of patients with this indication available in the literature.
- Trial name
- NCT03200106
- Testing
- Alfapump
- Where
- 3 sites in Germany, Switzerland and 1 more
- Volunteers
- 17 people
- Sponsor
- Sequana Medical N.V.
Malignant Ascites
At-Home Paracentesis for Cancer-Related Malignant Ascites (Paracentesis)
The goal of this study is to evaluate the change in symptoms for cancer-related malignant ascites who complete an at-home paracentesis procedure.
- Trial name
- Paracentesis (NCT07490626)
- Testing
- At-home Paracentesis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Utah
Pleural Effusion, Malignant
IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites
The purpose of this study was to evaluate the efficacy of IFN- Y combined with T cells in the treatment of refractory malignant pleural effusion and acties, using a multicenter, single-arm, open design.
- Trial name
- NCT05268172
- Testing
- IFN-γ and CIK cells, Tcm cells or CAR T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Affiliated Hospital of Jiangnan University
Malignant Pleural Effusion, Malignant Peritoneal Effusion
Safety and Efficacy Study of Virus Activated Killer Immune Cells (VAK) for Malignant Pleural and Peritoneal Effusion
Theory of VAK： 1. Immune cells (T cells for example) of cancer subjects may be domesticated by the tumor microenvironment, and have low efficacy to kill cancer cells.
- Trial name
- NCT05565014
- Testing
- Virus Activated Killer immune Cells, Saline
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sheng Hu
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Cancer of Stomach, Adenocarcinoma, Ascites, Malignant
Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites
This study is to evaluate the safety and efficacy of intraperitoneal injection of immune checkpoint inhibitor combined with zoledronic acid for the treatment of malignant ascites in gastric cancer.
- Trial name
- IPIZA (NCT06759064)
- Testing
- zoledronic acid plus Sintilimab intraperitoneal injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Qilu Hospital of Shandong University
Advanced Solid Tumors, Malignant Pleural Effusions
WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I)
This is a prospective, single-center, interventional, phase I, dose-escalation, single-arm study designed to evaluate the safety, tolerability, and preliminary efficacy of intrapleural/intraperitoneal infusion of WSK-IM02 in…
- Conditions
- Advanced Solid Tumors, Malignant Pleural Effusions, Malignant Ascites
- Trial name
- NCT07615894
- Testing
- WSK-IM02
- Where
- China
- Volunteers
- 9 people
- Sponsor
- WestVac Biopharma Co., Ltd.
Ovarian Cancer, Ovarian Neoplasms
AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites
Background: Some people with gastrointestinal or ovarian cancer also have ascites. That is free fluid built up in the abdomen. Researchers want to see if a new drug can affect some of the immune cells in the ascites.
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ascites, Gastrointestinal Cancer
- Trial name
- NCT02417753
- Testing
- AZD9150
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Ascites
PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites
The effect and safety of intraperitoneal infusion of PD-1 inhibitor is unclear for patients with peritoneal metastasis of advanced malignant tumors and malignant ascites.
- Trial name
- NCT05501340
- Testing
- Serplulimab, Molgramostim, Hypofractionated radiotherapy/Sterotactic body radiotherapy
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Malignant Ascites
A Study of Bevacizumab to Prevent Malignant Ascites
The purpose of this study is to determine the effectiveness of using Bevacizumab in the prevention of recurrent malignant ascites. Ascites is a debilitating and unpleasant complication of several types of cancer.
- Trial name
- NCT00908219
- Testing
- Bevacizumab
- Where
- 3 sites in United States
- Sponsor
- Baylor College of Medicine
Malignant Ascites, Cancer
A Study of M701 (EpCAM and CD3) in Malignant Ascites
This study is to investigate the safety, tolerability, PK, PD and immunogenicity of multiple ascending doses of M701 administered intraperitoneally to patients with malignant ascites caused by advanced solid tumors.
- Trial name
- NCT04501744
- Testing
- Cohort 1 of M701, Cohort 2 of M701, Cohort 3 of M701
- Where
- 2 sites in China
- Volunteers
- 35 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Malignant Ascites
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
The purpose of this study is to determine whether the investigational drug catumaxomab is a safe and effective treatment for recurrent symptomatic malignant ascites.
- Trial name
- NCT00326885
- Testing
- catumaxomab
- Where
- 18 sites in United States
- Volunteers
- 32 people
- Sponsor
- Neovii Biotech